BACKGROUND: Arginine vasopressin (AVP) is increasingly being used to treat advanced vasodilatory shock states due to sepsis, systemic inflammatory response syndrome (SIRS) or after cardiac surgery. There are currently no data available on long-term survival. PATIENTS AND METHODS: Demographic and clinical data, length of intensive care unit (ICU) stay, 1-year survival and causes of death after ICU discharge of 201 patients who received AVP because of advanced vasodilatory shock were collected retrospectively. RESULTS: The intensive care unit (ICU) survival rate was 39.8% (80 out of 201 patients). After ICU discharge 13 out of the 80 patients died within 1 year resulting in a 1-year survival rate of 33.3% (67 out of 201 patients). In nine patients, the cause of death was attributed to the same disease that led to ICU admission. One-year survival of patients with shock following cardiac surgery (42.1%) was higher than in patients suffering from SIRS (22.6%, p=0.005) or sepsis (28.3%, p=0.06). CONCLUSIONS: If advanced vasodilatory shock can be reversed with AVP and patients can be discharged alive from the ICU, 1-year survival rates appear to be reasonable despite severe multi-organ dysfunction syndrome (MODS).
BACKGROUND:Arginine vasopressin (AVP) is increasingly being used to treat advanced vasodilatory shock states due to sepsis, systemic inflammatory response syndrome (SIRS) or after cardiac surgery. There are currently no data available on long-term survival. PATIENTS AND METHODS: Demographic and clinical data, length of intensive care unit (ICU) stay, 1-year survival and causes of death after ICU discharge of 201 patients who received AVP because of advanced vasodilatory shock were collected retrospectively. RESULTS: The intensive care unit (ICU) survival rate was 39.8% (80 out of 201 patients). After ICU discharge 13 out of the 80 patients died within 1 year resulting in a 1-year survival rate of 33.3% (67 out of 201 patients). In nine patients, the cause of death was attributed to the same disease that led to ICU admission. One-year survival of patients with shock following cardiac surgery (42.1%) was higher than in patients suffering from SIRS (22.6%, p=0.005) or sepsis (28.3%, p=0.06). CONCLUSIONS: If advanced vasodilatory shock can be reversed with AVP and patients can be discharged alive from the ICU, 1-year survival rates appear to be reasonable despite severe multi-organ dysfunction syndrome (MODS).
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Crit Care Med Date: 2003-04 Impact factor: 7.598
Authors: Günter Luckner; Martin W Dünser; Stefan Jochberger; Viktoria D Mayr; Volker Wenzel; Hanno Ulmer; Stefan Schmid; Hans Knotzer; Werner Pajk; Walter Hasibeder; Andreas J Mayr; Barbara Friesenecker Journal: Crit Care Med Date: 2005-11 Impact factor: 7.598
Authors: Kevin B Laupland; David A Zygun; Christopher J Doig; Sean M Bagshaw; Lawrence W Svenson; Gordon H Fick Journal: Intensive Care Med Date: 2005-01-22 Impact factor: 17.440
Authors: Jean-Louis Vincent; Yasser Sakr; Charles L Sprung; V Marco Ranieri; Konrad Reinhart; Herwig Gerlach; Rui Moreno; Jean Carlet; Jean-Roger Le Gall; Didier Payen Journal: Crit Care Med Date: 2006-02 Impact factor: 7.598
Authors: Günter Luckner; Viktoria D Mayr; Stefan Jochberger; Volker Wenzel; Hanno Ulmer; Walter R Hasibeder; Martin W Dünser Journal: Crit Care Med Date: 2007-10 Impact factor: 7.598
Authors: James A Russell; Keith R Walley; Joel Singer; Anthony C Gordon; Paul C Hébert; D James Cooper; Cheryl L Holmes; Sangeeta Mehta; John T Granton; Michelle M Storms; Deborah J Cook; Jeffrey J Presneill; Dieter Ayers Journal: N Engl J Med Date: 2008-02-28 Impact factor: 91.245